HIV Diagnosis Market Research, 2032
The global hiv diagnosis market was valued at $1.9 billion in 2022, and is projected to reach $2.7 billion by 2032, growing at a CAGR of 3.9% from 2023 to 2032. Major factors driving the growth of the market are increase in unprotected sex among population and sharing needles, drugs or syringes for one or more patients in hospital settings, especially in under-developed or developing economies. For instance, according to the World Health Organization (WHO) in 2022, around 39 million individuals were living with HIV globally, out of which 1.3 million individuals were diagnosed with HIV newly in 2022. Further, among the 1.3 million HIV diagnosed individuals, 1.2 million are adults and about 50% of the HIV affected adults die within the few years. Thus, increase in HIV cases and deaths has increased its awareness in certain regions, further driving the growth of the HIV diagnosis market.
HIV is a virus known as Human Immunodeficiency Virus, which causes acquired immunodeficiency syndrome (AIDS). AIDS is the late stage of HIV infection that occurs when the body's immune system is badly damaged due to the virus. HIV diagnosis is the method of determining whether an individual is infected with the Human Immunodeficiency Virus (HIV), and it involves assessing risk factors, performing specific blood tests to detect HIV antibodies, antigens, or genetic material, and verifying positive results with additional tests. The test also includes assessing the individual's CD4 cell count and viral load to monitor disease progression and guide treatment decisions.
Key Takeaways
- By mode, the lab-based test segment dominated the global HIV Diagnosis Market in 2022.
- By test type, the antibody/antigen test segment acquired a major share in the global HIV Diagnosis Market in 2022.
- By end use, the diagnostic laboratories segment is expected to grow with a faster CAGR during the HIV Diagnosis Market forecast period.
- By region, North America dominated the market in terms of revenue in 2022. However, LAMEA is anticipated to grow at the highest CAGR during the forecast period.
Market Dynamics
The HIV Diagnosis Market size is primarily driven by increase in unprotected sex among population, administering illegal substances intravenously or use of shared needles, and contact with infected blood. HIV also can spread from parent to child during pregnancy, breastfeeding or childbirth. HIV destroys white blood cells called CD4 T cells, which play a vital role in aiding the body fight HIV disease. Lower count of CD4 T cells indicates a compromised immune response.
In addition, rise in R&D efforts to create self-test kits specially in low-income countries like those in African region such as Eswatini, Botswana, and Lesotho is contributing to the growth of the market.
Increase in initiatives by public organizations such as WHO, the U.S. Department of Health & Human Services, and other region/country-specific organizations offers heightened awareness and increased investment flow into the market as a result of these initiatives led by public organizations. There are certain awareness programs that offer insights into factors such as condom programming, Pre-exposure prophylaxis (PrEP), Post-exposure prophylaxis (PEP), Treatment as prevention (TasP), Voluntary medical male circumcision (VMMC), Harm reduction programming, and Behavioral interventions, and others. Thus, increase in awareness is expected to lead to increased HIV testing in most of the countries and drive the HIV diagnosis market growth. For instance, in July 2023, Ghana had launched an HIV Self-Testing (HIVST) program, which aims to empower Ghanaians with the ability to check their HIV status in the comfort and privacy of their homes. Among the various alternatives available under this program, one noteworthy method is the oral HIV self-test. Together with this approach, individuals can swab their upper and lower gums utilizing a specialized oral swab. This has further increased the number of HIV tests, which in turn has boosted the HIV Diagnosis Market Size in recent years.
Further, the launch of novel self-testing kits at lower costs or for free is expected to lead to more HIV testing, further driving the HIV Diagnostics Market. For instance, in March 2023, Centers for Disease Control and Prevention launched a project named Together TakeMeHome (TTMH), which will offer 1 million free HIV self-tests over the next five years for individuals living in the U.S. and Puerto Rico. In addition, there are small or local players from developing countries that offer cost efficient HIV testing kits. For instance, Mylab Discovery Solutions, a lab based in India offers rapid kits for the early and fast detection of sexually transmitted infections (STIs) such as HIV, Hepatitis C Virus (HCV), and Syphilis. These tests are easy to use, can be stored at room temperature, and can be deployed at point of care in resource-limited settings. In addition, these kits can be utilized at blood banks for the effective detection of transfusion-transmissible infections (TTIs) among blood donors and reducing their transmission.
Segments Overview
The HIV Diagnostics Market is segmented into mode, test type, end use, and region. By mode, the market is segregated into self-test and lab based. By test type the market is segregated into antibody/antigen test, viral load test/nucleic acid test, CD4 test, and test for early infant diagnosis. Antibody/antigen test is further segregated into HIV-1 screening tests, HIV-1 antibody confirmatory tests, and HIV-2 & Group Of diagnostic tests. By end use, the market is segregated into diagnostic laboratories, hospitals & clinics, and home settings. By region, the HIV diagnosis market share is segmented into North America, Europe, Asia-Pacific, and LAMEA.
By Mode
By mode segment, the lab-based test dominated the market in 2022 and is expected to continue this trend during the forecast period. Lab-based testing is more accurate and individuals who test positive can get help from the healthcare professional regarding the disease monitoring and progression. Lab-based HIV diagnosis is often included in existing healthcare systems, making it accessible in various healthcare settings, including hospitals, clinics, and laboratories. This incorporation facilitates coordination of care, linkage to treatment and support services, as well as follow-up monitoring for individuals diagnosed with HIV.
By Test Type
By test type, the viral load test/nucleic acid test segment is expected to register a faster CAGR during the forecast period. This is because most countries are increasingly using viral load testing to monitor HIV treatment. This trend may be enhanced by the use of point-of-care viral load technologies and dried blood spots.
Further, based on antibody/antigen test, the HIV-1 antibody confirmatory tests are expected to garner major share in 2022 and is expected to continue this trend during the forecast period thereby driving the growth of HIV Diagnosis market.
By End Use
By end use, the diagnostic laboratory segment dominated the market in 2022 and is expected to grow with a higher CAGR during the forecast period. The growth in diagnostic laboratory HIV diagnosis has increased in recent years considering the social stigma and discrimination behind such illnesses. Hence, individuals with HIV often visit diagnostic laboratories or private clinics to avoid the negative emotional well-being and mental health of people living with HIV thereby driving the growth of HIV Diagnosis industry.
By Region
By region, North America dominated the market in 2022 and is expected to continue this trend during the forecast period. This is due to the presence of majority of the HIV testing manufacturers in the U.S. as well as the support from government and other organizations related to awareness programs and reduction in prices of testing kits. However, LAMEA is expected to grow with a faster CAGR during the forecast period. Africa is the epicenter of HIV globally and the cases are growing at a faster rate in certain African countries. For instance, according to UNAIDS, an estimated 67% of the population in Sub-Saharan Africa (SSA) are living with HIV as of 2021. Further, in key Sub-Saharan Africa, key populations accounted for about 51% of new infections in 2021.
Competitive Analysis
Major players have adopted product launch as their main strategy in thereby driving the growth of HIV Diagnosis market, especially the launch of home-based rapid self-test kits. For instance, in 2023, India-based INVEX Health launched India's first oral HIV self-test. It detects both HIV1 and HIV2 antibodies utilizing the human oral mucosa. It is an easy, painless, and less complicated test kit that gives rapid results in around 20 minutes.
Recent Developments in HIV Diagnosis Industry
In February 2023, Mylab Discovery Solutions, a lab based in India launched its rapid testing kits for the early and fast detection of sexually transmitted infections (STIs) such as Human Immunodeficiency Virus (HIV), Hepatitis C Virus (HCV), and Syphilis.
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the HIV diagnosis market analysis from 2022 to 2032 to identify the prevailing HIV diagnosis market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the HIV diagnosis market share segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global HIV diagnosis market trends, key players, market segments, application areas, and market growth strategies.
HIV Diagnosis Market Report Highlights
| Aspects | Details |
 Forecast period | 2022 - 2032 |
 Report Pages | 290 |
 By Mode |
|
 By Test Type |
|
 By End-use |
|
 By Region |
|
 Key Market Players | Hologic Inc., F Hoffman La Roche Ltd, Bio-Rad Laboratories, Inc. , Mylan N.V., Abbott Laboratories, Danaher Corporation, Siemens Healthcare Private Limited, Qiagen NV., Merck & Co. Inc., Gilead Sciences, Inc. |
Analyst Review
The HIV diagnosis market is expected to grow at a considerable CAGR during the forecast period. The HIV diagnosis market is primarily driven by rise in demand for accurate and accessible diagnosis. While new infections are declining, timely and accurate diagnosis remains crucial for early intervention and treatment. Further, point of care diagnostics, rapid diagnostic tests, and self-testing kits are broadening access and increasing the variety of available options. Technological advancements such as telemedicine and data analytics offer opportunities for remote diagnosis, monitoring, and follow-ups.
However, high costs, limited availability in Low- or Middle-Income Country (LMIC) and infrastructure gaps impede access to accurate and timely diagnosis. Furthermore, sustaining engagement in testing programs and promoting awareness remain crucial to reaching undiagnosed individuals.
Furthermore, North America dominated the HIV diagnosis market in 2022 and is expected to continue this trend during the forecast period, owing to advanced healthcare infrastructure, substantial investments in R&D, and the presence of major key players in the region. However, the LAMEA region is projected to emerge as the fastest-growing market in global HIV diagnosis, driven by lack of access to basic healthcare among individuals living in poverty.
Therefore, accurate and accessible diagnosis is the cornerstone of effective HIV response. CXOs must prioritize innovations and strategies that expand access, address affordability and leverage technology. By tackling changes and seizing opportunities, CXOs can contribute to achieving the UNAIDS 95-95-95 target and ending AIDS as a public threat by 2030.
Trends such as the rise in self-testing or home-based testing is one of the upcoming trends in HIV Diagnosis Market
The viral load test/nucleic acid test segment is expected to register a faster CAGR during the forecast period.
North America is the largest regional market for HIV Diagnosis Market
The global HIV diagnosis market was valued at $1.9 billion in 2022, and is projected to reach $2.7 billion by 2032, growing at a CAGR of 3.9% from 2023 to 2032.
F. Hoffman-La Roche Ltd., Bio-Rad Laboratories, Inc., Abbott, Hologic, and QIAGEN are the top companies to hold the market share in HIV Diagnosis Market
Yes, competitive landscape is included in the HIV Diagnosis Market
High cost of Nucleic Acid Test and low level of awareness specially in developing economies is one of the major restraints of HIV Diagnosis Market
Rise in number of HIV cases and launch of novel self-test kits and Increase in number of blood transfusion and blood donations are the two major drivers of HIV Diagnosis Market
Loading Table Of Content...
Loading Research Methodology...
